A Combined Chemical and Genetic Approach for the Generation of Induced Pluripotent Stem Cells

Shi, Yan; Tae, Jeong; Desponts, Caroline; Hahm, Heung Sik; Schöler, Hans R.; Ding, Shilei

doi:10.1016/j.stem.2008.06.003

Cited by 219 publications

(311 citation statements)

References 0 publications

Supporting

Mentioning

296

Contrasting

Unclassified

Order By: Relevance

“…Actual examples of leukemia developing in 2 of 10 patients with X-linked severe combined immunodeficiency who underwent gene therapy with a retrovirus vector have been reported [33]. Fortunately, in recent years, iPS cells have been successfully produced without using retroviruses or lentiviruses by means of transient gene expression [32,[34][35][36] and protein transduction [37,38], and by replacing some of the previously transduced genes with drug treatment [39,40]. The use of iPS cells produced without inserting exogenous genes appears to be preferable for cell transplantation therapy.…”

Section: Future Prospects and Tasksmentioning

confidence: 99%

Cell Therapy for Spinal Cord Injury by Neural Stem/Progenitor Cells Derived from iPS/ES Cells

et al. 2011

View full text Add to dashboard Cite

Reports of functional recovery from spinal cord injury after the transplantation of rat fetus-derived neural stem cells and embryonic stem cells has raised great expectations for the successful clinical use of stem cell transplantation therapy. However, the ethical issues involved in destroying human embryos or fertilized oocytes to obtain stem cells have been a major obstacle to developing clinically useful stem cell sources, and the transplantation of stem cells isolated from other human embryonic tissues has not yet been developed for use in clinical applications. Recently, induced pluripotent stem cells, which can serve as a source of cells for autologous transplantation, have been attracting a great deal of attention as a clinically viable alternative to stem cells obtained directly from tissues. In this review, we outline the neural induction of mouse embryonic stem cells and induced pluripotent stem cells, their therapeutic efficacy in spinal cord injury, and their safety in vivo.

show abstract

Section: Future Prospects and Tasksmentioning

confidence: 99%

Cell Therapy for Spinal Cord Injury by Neural Stem/Progenitor Cells Derived from iPS/ES Cells

et al. 2011

View full text Add to dashboard Cite

show abstract

“…To this end, several inhibitors of DNA and histone methyltransferase, as well as histone deacetylase (HDAC) inhibitors have been found to dramatically improve reprogramming efficiency (Huangfu et al, 2008a;Shi et al, 2008).…”

Section: Change Of Epigenetic Landscapementioning

confidence: 99%

“…Some small molecules could replace certain reprogramming factors. For example, the G9a histone methyltransferase inhibitor, BIX-01294, has been shown to be able to substitute cMyc and improve the reprogramming efficiency of neural stem cells by Oct4 and Klf4 (Shi et al, 2008). A-83-01, a TGFβ kinase/activin receptor-like kinase (ALK5) inhibitor can replace Sox2 through inducing Nanog and cMyc expression (Ichida et al, 2009;Maherali and Hochedlinger, 2009) and promoting mesenchymal-to-epithelial transition .…”

Section: Chemical Compoundsmentioning

confidence: 99%

Mechanism and methods to induce pluripotency

Wang

2011

Protein Cell

View full text Add to dashboard Cite

Pluripotent stem cells are able to self-renew indefinitely and differentiate into all types of cells in the body. They can thus be an inexhaustible source for future cell transplantation therapy to treat degenerative diseases which currently have no cure. However, non-autologous cells will cause immune rejection. Induced pluripotent stem cell (iPSC) technology can convert somatic cells to the pluripotent state, and therefore offers a solution to this problem. Since the first generation of iPSCs, there has been an explosion of relevant research, from which we have learned much about the genetic networks and epigenetic landscape of pluripotency, as well as how to manipulate genes, epigenetics, and microRNAs to obtain iPSCs. In this review, we focus on the mechanism of cellular reprogramming and current methods to induce pluripotency. We also highlight new problems emerging from iPSCs. Better understanding of the fundamental mechanisms underlying pluripotenty and refining the methodology of iPSC generation will have a significant impact on future development of regenerative medicine.

show abstract

“…55 The reprogramming efficiency is improved by lowering the barrier of histone modifications. Agents that have been reported to increase iPSC generation include BIX-01294, which is an inhibitor of G9a histone H3K9 methyltransferase, 60) and valproic acid (VPA), trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA) and sodium butyrate (NaB), which all are inhibitors of histone deacetylase. 61),62) NaB promotes the reprogramming only in the presence of exogenously expressed c-Myc at the early stage of reprogramming.…”

Section: Factors and Pathway Critical For Ips Cell Generationmentioning

confidence: 99%

Induction of pluripotency by defined factors

Okita

Yamanaka

2010

Experimental Cell Research

View full text Add to dashboard Cite

Abstract:The "reversion of cell fate from differentiated states back into totipotent or pluripotent states" has been an interest of many scientists for a long time. With the help of knowledge accumulated by those scientists, we succeeded in converting somatic cells to a pluripotent cell lineage by the forced expression of defined factors. These established induced pluripotent stem (iPS) cells have similar features to embryonic stem (ES) cells, including pluripotency and immortality. The iPS cell technology provides unprecedented opportunities for regenerative medicine and drug discovery.

show abstract

A Combined Chemical and Genetic Approach for the Generation of Induced Pluripotent Stem Cells

Cited by 219 publications

References 0 publications

Cell Therapy for Spinal Cord Injury by Neural Stem/Progenitor Cells Derived from iPS/ES Cells

Cell Therapy for Spinal Cord Injury by Neural Stem/Progenitor Cells Derived from iPS/ES Cells

Mechanism and methods to induce pluripotency

Induction of pluripotency by defined factors

Contact Info

Product

Resources

About